PCSK9 inhibitors: Going forward and beyond

被引：1
|
作者：
Attar, Armin [1 ]
机构：
[1] Shiraz Univ Med Sci, Dept Cardiovasc Med, TAHA Clin Trial Grp, Shiraz, Iran
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 08期
关键词：
LDL-CHOLESTEROL; SECONDARY ANALYSIS; CLINICAL-EFFICACY; EVOLOCUMAB; SAFETY; STATIN;
D O I：
10.1177/2047487320916964
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：803 / 804
页数：2
相关论文
共 50 条
  • [41] High glucose effects on PCSK9 expression in aortic VSMC: role of PCSK9 inhibitors
    Barale, C.
    Melchionda, E.
    Russo, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S421 - S421
  • [42] Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias
    Rached, Fabiana
    Santos, Raul D.
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (07)
  • [43] PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
    Paciullo, Francesco
    Momi, Stefania
    Gresele, Paolo
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (03) : 359 - 367
  • [44] Role of PCSK9 beyond liver involvement
    Cariou, Bertrand
    Si-Tayeb, Karim
    Le May, Cedric
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (03) : 155 - 161
  • [45] Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction
    Nakamura, Akihiro
    Kanazawa, Masanori
    Kagaya, Yuta
    Kondo, Masateru
    Sato, Kenjiro
    Endo, Hideaki
    Nozaki, Eiji
    JOURNAL OF CARDIOLOGY, 2020, 76 (04) : 395 - 401
  • [46] Cholestrol and stroke: Roll of PCSK9 inhibitors
    Castilla-Guerra, L.
    Fernandez-Moreno, M. C.
    Rico-Corral, M. A.
    NEUROLOGIA, 2019, 34 (03): : 198 - 203
  • [47] PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (06) : 590 - 601
  • [48] Limitations of cholesterol lowering with PCSK9 inhibitors
    Thompson, Gilbert
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (04): : 241 - 243
  • [49] PCSK9 Inhibitors Current clinical Relevance
    Vogt, A.
    INTERNIST, 2017, 58 (02): : 196 - 201
  • [50] Inhibitors of PCSK9 and dyslipidemia: the clinical evidence
    Norata, Giuseppe Danilo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2014, 15 (05) : 301 - 305
12345